Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain

Synapse

Volumn 29, Issue 2, 1998, Pages 116-127

  Madras, Bertha K ^a   Gracz, Lawrence M ^a   Fahey, Michele A ^a   Elmaleh, David ^d   Meltzer, Peter C ^b   Liang, Anna Y ^b   Stopa, Edward G ^c   Babich, John ^d   Fischman, Alan J ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ORGANIX INC   (United States)

^c BROWN UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cocaine; Dopamine neurons; Dopamine transporter; Neurodegenerative diseases; Parkinson's disease; SPECT imaging

Indexed keywords

ALTROPANE; DOPAMINE; DOPAMINE TRANSPORTER; IODINE 125; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BASAL GANGLION; BINDING AFFINITY; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; BRAIN; BRAIN CHEMISTRY; CARRIER PROTEINS; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEOSTRIATUM; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031897730     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199806)29:2<116::AID-SYN3>3.0.CO;2-A     Document Type: Article

References (68)

1. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse, 12:27-36.
2. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol. Pharmacol., 47:779-786.
3. Brownell, A.-L., Elmaleh, D.R., Meltzer, P.C., Shoup, T.M., Brownell, G.L., Fischman, A.J., and Madras, B.K. (1996) Cocaine congeners as PET imaging probes for dopamine terminals. J. Nucl. Med., 37:1186-1192.
4. 3H]WIN 35,428) in the monkey brain. Synapse, 6:189-195.
5. Ciliax, B.J., Heilman, C., Demchyshyn, L.L., Pristupa, Z.B., Ince, E., Hersch, S.M., Niznik, H.B., and Levey, A.I. (1994) The dopamine transporter: Immunochemical characterization and localization in brain. J. Neurosci., 15:1714-1723.
6. Clarke, R.L., Daum, S.J., Gambino, A.J., Aceto, M.D., Pearl, J., Levitt, M., Cumiskey, W.R., and Bogado, E.F. (1973) Compounds affecting the central nervous system. 4. 3β-phenyltropane-2-carboxylic esters and analogs. J. Med. Chem., 16:1260-1267.
7. 3H]imipramine. J. Pharmacol. Exp. Ther., 242:364-371.
8. Elmaleh, D.R., Fischman, A.J., Shoup, T.M., Byon, C., Hanson, R.N., Liang, A.Y., Meltzer, P.C., and Madras, B.K. (1996) Preparation and biological evaluation of iodine-125-IACFT: A selective SPECT agent for imaging dopamine transporter sites. J. Nucl. Med., 37:1197-1202.
9. Emond, P., Garreau, L., Chalon, S., Boazi, M., Caillet, M., Bricard, J., Frangin, Y., Mauclaire, L., Besnard, J.-C., and Guilloteau, D. (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(3′,4′- disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem., 40:1366-1372.
10. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse, 16:93-193.
11. 123I]IACFT): Initial experience in humans. Neuroscience-Net, 1: Article #00010, HTTP://WWW.NEUROSCIENCE-.COM.
12. Fischman, A.J., Babich, J.W., Elmaleh, D.R., Barrow, S.A., Meltzer, P.C., and Madras, B.K. (1997) SPECT imaging of dopamine transporter sites in normal and MPTP treated rhesus monkeys. J. Nucl. Med., 38:144-150.
13. Fischman, A.J., Bonab, A.A., Babich, J.W., Palmer, P., Alpert, N.M., Elmaleh, D.R., Barrow, S.A., Graham, W., Meltzer, P.C., Hanson, R.H., and Madras, B.K. (1998) Rapid detection of Parkinson's disease by SPECT with Altropane: A selective ligand for dopamine transporters. Synapse, 29:128-141.
14. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann. Neurol., 34:423-431.
15. Garreau, L., Emond, P., Belzung, C., Guilloteau, D., Frangin, Y., Besnard, J.-C., and Chalon, S. (1997) N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(3′,4′- dichlorophenyl)nortropane (β-CDIT), a tropane derivative: Pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain. J. Pharmacol. Exp. Ther., 282:467-474.
16. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J., and Gerhardt, G.A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature, 380:252-255.
17. Goodman, M.M., Kung, M.-P., Kabalka, G.W., Kung, H.F., and Switzer, R. (1994) Synthesis and characterization of radioiodinated N-(3-Iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: Potential dopamine reuptake site imaging agents. J. Med. Chem., 37:1535-1542.
18. Goodman, M.M., Keil, R., Shoup, T.M., Eshima, D., Eshima, L., Kilts, Cl, Votaw, J., Camp, V.M., Votaw, D., Smith, E., Kung, M.-P., Malveaux, E., Watts, R., Huerkamp, M., Wu, D., Garcia, E., and Hoffman, J.M. (1997) Fluorine-18-FPCT: A PET radiotracer for imaging dopamine transporters. J. Nucl. Med., 38:119-126.
19. 11C]-CFT and PET in a primate model of parkinsonism. Neuroreport, 3:265-268.
20. Innis, R.B. (1994) Single-photon emission tomography imaging of dopamine terminal innervation: A potential clinical tool in Parkinson's disease. Eur. J. Nucl. Med., 21:1-5.
21. Innis, R., Seibyl, J.P., Scanley, B.E., Laruelle, M., Abi-Dargham, A., Wallace, E., Baldwin, R.M., Zea-Ponce, Y., Zogbi, S., Wang, S., Gao, Y., and Neumeyer, J.L. (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. USA, 90:11965-11969.
22. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J. Neurochem., 49:617-621.
23. 3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol. Pharmacol., 26:35-44.
24. Kaufman, M.J., and Madras, B.K. (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse, 9:43-19.
25. 125I]RTI-55. Synapse, 12:99-111.
26. 3H]WIN 35,428) accumulation in dopamine regions of monkey brain: Comparison of a mature and an aged monkey. Brain Res., 611:322-325.
27. 3H]CFT. Synapse, 9:177-187.
28. Kish, S.J., Shannak, K., and Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 318:876-880.
29. Kuhar, M.J., Sanchez-Roa, P.M., Wong, D.F., Dannals, D.F., Grigoriadis, D.E., Lew, R., and Milberger, M. (1990) Dopamine transporter: Biochemistry, pharmacology and imaging. Eur. Neurol., 30:15-20.
30. Lindsay, R.M. (1994) Neurotrophic growth factors and neurodegenerative diseases: Therapeutic potential of neurotrophins and ciliary neurotrophic factor. Neurobiol. Aging, 15:249-251.
31. 3H]WIN 35,428 binding sites in human striatum. Brain Res., 628:17-25.
32. 3H]Cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther., 251:131-141.
33. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane. Mol. Pharmacol., 36:518-524.
34. 3H]Lu19-005: Markers for cocaine receptors/dopamine nerve terminals in Parkinson's disease. Soc. Neurosci. Abst., 16:14.
35. 3H]cocaine receptors. Pharmacol. Biochem. Behav., 35:949-953.
36. Madras, B.K., Elmaleh, D.R., Meltzer, P.C., and Brownell, A.-L. (1994) Positron emission tomography of the dopamine transporter. NIDA Res. Monograph, 138. In: Imaging Techniques in Medications Development: Preclinical and Clinical Aspects. H. Sorer and R.S. Rapaka, eds., pp. 57-69.
37. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse, 22:239-246.
38. Madras, B.K., Brackett, T., Alpert, N., Bonab, A., and Fischman, A.J. (1997) PET imaging of the dopamine transporter in parkinsonian monkeys: A window on dopamine neuron regeneration? Soc. Neurosci. Abstr., 23:295.
39. 125I]Altropane, a SPECT imaging probe for dopamine neurons. I. Dopamine transporter binding in primate brain. Synapse, 29:93-104.
40. 125I]Altropane, a SPECT imaging probe for dopamine neurons. II. Distribution to dopamine-rich regions of primate brain. Synapse, 29:105-115.
41. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am. J. Psychiatry, 152:1359-1361.
42. Mash, D.C., Staley, J.K., Doepel, F.M., Young, S.N., Ervin, F.R., and Palmour, R.M. (1996) Altered dopamine transporter densities in alcohol-preferring vervet monkeys. Neuroreport, 7:457-462.
43. Meegalla, S.K., Plossl, K., Kung, M.-P., Chumpradit, S., Stevenson, D.A., Kushner, S.A., McElgin, W.T., Mozley, P.D., and Kung, H.F. (1997) Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J. Med. Chem., 40:9-17.
44. Meltzer, P.C., Liang, A.Y., Brownell, A.-L., Elmaleh, D.R., and Madras, B.K. (1993) Substituted 3-phenyltropane analogs of cocaine: Synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem., 36:855-862.
45. 99mSPECT imaging agent which targets the dopamine transporter in primate brain. J. Med. Chem., 40:1835-1844.
46. Neumeyer, J.L., Tamagnan, G., Wang, S., Gao, Y., Milius, R.A., Kula, N.S., and Baldessarini, R.J. (1996) N-Substituted analogs of 2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat. J. Med. Chem., 39:543-547.
47. Niznik, H.B., Fogel, E.F., Fassos, F.F., and Seeman, P. (1991) The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate. J. Neurochem., 56:192-198.
48. Patel, A., Uhl, G., and Kuhar, M.J. (1993) Species differences in dopamine transporters: Post-mortem changes and glycosylation differences. J. Neurochem., 61:496-500.
49. 18F-DOPA positron emission tomography study. Ann. Neurol., 41:222-229.
50. Pilotte, N.S., Sharpe, L.G., Rountree, S.D., and Kuhar, M.J. (1996) Cocaine withdrawal reduces dopamine transporter binding in the shell of the nucleus accumbens. Synapse, 22:87-92.
51. Ricaurte, G.A., Guillery, R.W., Seiden, L., Schuster, C.R., and Moore, R.Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res., 235:93-103.
52. 3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol., 329:227-235.
53. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol., 38:589-598.
54. 3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse, 25:163-15.
55. Staley, J.K., Hearn, W.L., Ruttenber, A.J., Wetli, C.V., and Mash, D.C. (1994) High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmacol. Exp. Ther., 271:1678-1685.
56. 125I]RTI-121. Synapse, 21:364-372.
57. Steiner, J.P., Hamilton, G.S., Ross, D.T., Valentine, H.L., Guo, H., Connolly, M.A., Liang, S., Ramsey, C., Li, J.-H., Huang, W., Howorth, P., Soni, R., Fuler, M., Sauer, H., Nowotnik, A.C., and Suzdak, P.D. (1997) Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. USA, 94:2019-2024.
58. Tiihonen, J., Kuikka, J., Bergstrom, K., Hakola, P., Karhu, J., Ryynanen, O.P., and Fohr, J. (1995) Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat. Med. 1:654-657.
59. van Dyck, C.H., Seibyl, J.P., Malison, R.T., Laruelle, M., Wallace, E., Zoghbi, S.S., Zea-Ponce, Y., Baldwin, R.M., Charney, D.S., Hoffer, P.B., and Innis, R.B. (1995) Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J. Nucl. Med., 36:1175-1181.
60. Vaughan, R.A., Brown, V.L., McCoy, M.T., and Kuhar, M.J. (1996) Species- and brain region-specific dopamine transporters: Immunological and glycosylation characteristics. J. Neurochem., 66:2146-2152.
61. Volkow, N.D., Gatley, S.J., Fowler, J.S., Chen, R., Logan, J., Dewey, S.L., Ding, Y.-S., Pappas, N., King, P., MacGregor, R.R., Kuhar, M.J., Carroll, F.I., and Wolf, A.P. (1995) Long-lasting inhibition of in vivo cocaine binding to dopamine transporters by 3β-(4-iodophenyl)tropane-2-carboxylic acid methyl ester:RTI-55 or bCIT. Synapse, 19:206-211.
62. Volkow, N.D., Ding, Y.-S., Fowler, J.S., Wang, G.J., Logan, J., Gatley, S.J., Hitzemann, R., Smith, G., Fields, S.D., and Gur, R. (1996a) Dopamine transporters decrease with age. J. Nucl. Med., 37:554-559.
63. Volkow, N.D., Wang, G.-J., Fowler, J.S., Gatley, S.J., Ding, Y.-S., Logan, J., Dewey, S.L., Hitzemann, R., and Lieberman, J. (1996b) Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc. Natl. Acad. Sci. USA, 93:10388-10392.
64. Wilson, J.M., Levey, A.I., Rajput, A., Ang, L., Guttman, M., Shannak, K., Niznik, H.B., Hornykiewicz, O., Pifl, C., and Kish, S.J. (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinsons disease. Neurology, 47:718-726.
65. 11C]WIN 35,428. Synapse, 15:130-142.
66. Wong, D.F., Harris, J.C., Naidu, S., Yokoi, F., Marenco, S., Dannals, R.F., Ravert, H.T., Yaster, M., Evans, A., Rousset, O., Bryan, R.N., Gjedde, A., Kuhar, M.J., and Breese, G.R. (1996) Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc. Natl. Acad. Sci. USA, 93:5539-5543.
67. Zelnik, N., Angel, I., Paul, S.M., and Kleinman, J.E. (1986) Decreased density of human striatal dopamine uptake sites with age. Eur. J. Pharmacol., 126:175-176.
68. Zetterstrom, R.H., Solomin, L., Jansson, L., Hoffer, B.J., Olson, L., and Perlmann, T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science, 276:248-250.